Anixa Biosciences Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Mailing Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Phone
408-708-9808
Fiscal Year End
1031
EIN
112622630
Financial Overview
FY2025
$21.59M
Total Assets
$20.00M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 10-Q Quarterly financial report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 28, 2026 | View on SEC |
| 10-K Annual financial report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 6, 2026 | View on SEC |
Annual Reports
10-K
January 12, 2026
- Focuses on cutting-edge Cancer Vaccines and CART Therapeutics.
- Stock trades on The NASDAQ Stock Market LLC under ticker ANIX.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.